Last reviewed · How we verify

Bupivacaine 0.25% with Epinephrine

Holy Cross Hospital, Florida · FDA-approved active Small molecule

Bupivacaine blocks sodium channels in nerve cell membranes to produce local anesthesia, while epinephrine causes vasoconstriction to prolong the anesthetic effect and reduce systemic absorption.

Bupivacaine blocks sodium channels in nerve cell membranes to produce local anesthesia, while epinephrine causes vasoconstriction to prolong the anesthetic effect and reduce systemic absorption. Used for Local and regional anesthesia for surgical procedures, Infiltration anesthesia, Nerve blocks.

At a glance

Generic nameBupivacaine 0.25% with Epinephrine
Also known asMarkyrene
SponsorHoly Cross Hospital, Florida
Drug classLocal anesthetic with vasopressor
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Bupivacaine is a long-acting amide local anesthetic that reversibly inhibits sodium influx into nerve fibers, preventing depolarization and conduction of nerve impulses. The addition of epinephrine (adrenaline) causes vasoconstriction of local blood vessels, which slows the systemic absorption of bupivacaine, extends its duration of action, and reduces the risk of systemic toxicity.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results